Vitexin

Other Names

4H-1-Benzopyran-4-one, 8-β-D-glucopyranosyl-5,7-dihydroxy-2-(4-hydroxyphenyl)-5,7,4'-Trihydroxyflavone-8-glucoside5,7-Dihydroxy-2-(4-hydroxyphenyl)-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one5,7-Dihydroxy-8-beta-D-glucopyranosyl-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one8-beta-D-glucopyranosyl-apigenin8-C-β-D-Glucopyranosylapigenin8-D-glucosyl-4',5,7-trihydroxyflavone8-Glucopyranosylapigenin8-Glucosylapigenin8-β-D-GlucopyranosylapigeninApigenin 8-glucosideApigenin-8-C-glucosideApigenin-8-C-β-D-glucopyranosideFlavone, 8-D-glucosyl-4',5,7-trihydroxy-MujingsuOrientosideVitexina

Synopsis

Vitexin: A Comprehensive Encyclopedic Reference

1. Identity: Chemical, Botanical, and Structural Profile

1.1 Chemical Identity and Nomenclature

Vitexin (5,7,4′-trihydroxyflavone-8-glucoside) is a C-glycosylated flavonoid compound widely present in various kinds of plants and is an active ingredient in many traditional Chinese medicines and foods. Chemically, vitexin is known as 8-D-glucosyl-4′,5,7-trihydroxy-flavone, with the molecular formula C₂₁H₂₀O₁₀ and a molecular weight of 432.38 g/mol. The compound is registered under CAS number 3681-93-4. The scientific name of vitexin is 5,7-dihydroxy-2-(4-hydroxyphenyl)-8-{(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl}chromen-4-one. It is also known by the synonyms 4,5,7-trihydroxyflavone, 8-C-glucosylapigenin, apigenin 8-C-glucoside, and orientoside.

Vitexin features a distinctive C-glycosidic bond at the 8-position of its apigenin backbone, contributing to its enhanced metabolic stability compared to O-glycosidic flavonoids. It is a relatively small polar molecule with a LogP value of 1.28. Structurally, vitexin consists of an apigenin backbone with a carboside group attached at position 8. The addition of the carboside group significantly enhances its antioxidant and antitumor properties.

Vitexin contains seven hydroxyl groups, which may play a crucial role in its biological activity. The dihydroxyl structure in the A ring has been identified as an effective contributor to free-radical scavenging in flavonoids. The relative stability of hydroxyl radicals in vitexin has been ranked as 4′-OH > 7-OH > 5-OH.

1.2 Botanical Sources and Natural Occurrence

Vitexin (apigenin-8-C-β-D-glucopyranoside) is a naturally occurring flavonoid glycoside widely distributed in medicinal and edible plants, such as mung bean, beetroot, hawthorn, bamboo, Passiflora, and others. Vitexin is a chemical compound found in many plants, such as buckwheat, hawthorn (Crataegus spp.), Echinodorus, bamboo (Phyllostachys), mung bean (Vigna radiata), and Passiflora.

Vitexin is found as a major polyphenol in food sources such as mung beans. Mung bean is consumed as soup and is a popular food item in China and many Asian countries, where it is believed to control heatstroke. Vitexin and isovitexin are identified as the major polyphenols in the mung bean.

Vitexin is an apigenin flavone glucoside found in the passion flower, Vitex agnus-castus (chaste tree or chasteberry), in the Phyllostachys nigra bamboo leaves, in the pearl millet (Pennisetum millet), and in hawthorn. The main chemical compounds of Vitex agnus-castus include vitexin, orientin, apigenin, casticin, agnuside, p-hydroxybenzoic acid, di-C-glycosides, alkaloids, diterpenoids, and the iridoid compound aucubin.

1.3 Isomers, Related Compounds, and Common Preparations

Isovitexin (apigenin-6-C-glucoside) is an isomer of vitexin that also exists in plants containing vitexin, such as pigeon peas, passion flowers, bamboo, mimosa, and wheat leaves. The structural difference is that vitexin carries its glucose unit at the C-8 position of the apigenin backbone, while isovitexin carries it at C-6. Vitexin also occurs naturally in glycosylated derivative forms, including vitexin-2-O-rhamnoside and vitexin-4-O-glucoside, which are present in hawthorn extracts and have been studied separately for pharmacokinetic properties.

In commercial supplement contexts, vitexin is most commonly encountered as a constituent within standardized plant extracts rather than as an isolated pure compound. The dried fruits of Vitex agnus-castus are the most commonly used medicinal form, but today Vitex is available in a range of pharmaceutical forms, including tinctures, fluid extracts, tablets, and homeopathic preparations. Vitexin-containing hawthorn extracts are standardized to flavonoid content in European herbal medicine. Pure isolated vitexin is also available as a research reagent and is being investigated in nanoparticle and liposomal delivery systems to address its inherently low aqueous solubility.

2. Traditional and Historical Use

2.1 Ancient Greek and European Traditions

Throughout recorded history, some of the same herbal medicines commonly used today were recognized and prescribed by ancient doctors—handed down from unknown antiquity. One such plant was called agnos by the ancient Greeks, over 2,000 years ago; then agnus castus throughout the Middle Ages and Renaissance. Today one can still buy these small spicy fruits in European herb markets by the same name. The ancients ascribed many magical powers to this plant, and it was considered an important healing herb among the common people during the following centuries.

The Romans used a drink prepared from the plant's seeds to decrease libido. In ancient Greece, young women celebrating the festival of Demeter wore chasteberry blossoms to show that they were remaining chaste in honor of the goddess. For monks in the Middle Ages, chasteberry was used for similar purposes, which led to the common name "monk's pepper."

2.2 Traditional Chinese Medicine and Asian Traditions

Viticis Fructus has been used as a traditional Chinese medicine for thousands of years to treat illness such as colds, headache, vertigo, anesthesia, and hyperkinesias. The traditional use of the fruit can be traced back to ancient times, with its earliest recorded mention appearing in Shen Nong's Classic of Materia Medica of China. This historical text commended it for its medicinal properties and addressed it as a remedy for various afflictions. Among its benefits, it was believed to alleviate conditions like cold and heat between the tendons and bones, address dampness impediment, enhance vision by brightening the eyes, strengthen the teeth, unblock the "nine orifices" (body openings), and even eliminate taeniasis caused by tapeworm infection.

Most species of the Vitex genus that are used in traditional medicine are found in southwest Asian countries like India, China, Nepal, Sri Lanka, Bangladesh, Malaysia, and others including Indonesia, Egypt, Iran, Morocco, Brazil, and Mexico. Traditionally, Vitex plants have long been used for different types of treatment of menstrual disorders, fertility problems, menopausal symptoms, diarrhea, asthma, fever, cold, headache, migraine, gastrointestinal infections, and breast pain.

Vitexin is present in various plants including hawthorn, mung bean, beetroot, passion flowers, bamboo, and gaillardia. From ancient times, these plants have been utilized as food and medicine in Asia. Still today they are widely used for the treatment of digestive-related disorders, detoxification, dermal diseases, sunstroke, inflammation, and various other diseases and disorders.

2.3 Unani and Iranian Traditional Medicine

A hot decoction of the seeds of Vitex is used as a contraceptive, and as a hot decoction and vaginal pessary for an emmenagogue in Unani traditional medicine. In Iranian traditional medicine, Vitex leaves and fruits are used for increasing milk production in women. The fruits of Vitex rotundifolia have been used as a folk medicine for the treatment of headache, cold, migraine, eye pain, and female hormonal conditions.

2.4 Preparations and Forms in Traditional Use

The Vitex tree, including its leaves and fruits, has been used for herbal remedies in the form of pastes, decoctions, and dried fruits since ancient times. In Chinese herbal medicine, the dried fruit (Viticis Fructus) is incorporated into classical prescriptions such as XiangSuSan. Most of the plant parts—such as fruit, leaf, root, flower, and stem—of Vitex rotundifolia and Vitex trifolia have medicinal value, but the most studied and used are the fruits. In Asia, the fruit and leaves of these species are widely used as medicinal materials.

3. Chemical Constituents and Mechanisms of Action

3.1 Active Compounds in Vitexin-Containing Plants

Vitexin is the principal bioactive flavonoid of interest but typically co-occurs in plant sources with structurally related compounds. The C. nutans extract is rich with six known C-glycosyl flavones, including vitexin, isovitexin, shaftoside, isomollupentin 7-O-β-glucopyranoside, orientin, and isoorientin. In hawthorn, vitexin co-occurs with vitexin-2-O-rhamnoside, procyanidins, and hyperoside. In mung bean, it co-occurs with isovitexin, flavonols, and various polysaccharides and peptides with complementary bioactivities.

3.2 Antioxidant Mechanisms

Vitexin has been proven capable of donating electrons and acts as a good radical scavenger. Both in vitro and in vivo data show that vitexin can enhance the body's antioxidant capacity and reduce the occurrence of oxidative stress. Vitexin has been proven to produce a powerful antioxidant defense by acting as an effective oxygen free radical scavenger to increase the activity of antioxidant enzymes and upregulate the protein of antioxidant reactions.

Vitexin blocks the production of reactive oxygen species (ROS) and increases the activity of antioxidant enzymes (SOD, GSH-Px, and CAT) via activation of PPARγ, both in vivo and in vitro. The C-8 glycosidic attachment is structurally significant for this activity: because of its C-8 glucoside configuration, vitexin causes a reduction of bond dissociation enthalpy compared to the aglycone apigenin, conferring improved free-radical scavenging capacity.

3.3 Anti-Inflammatory Mechanisms

Vitexin can attenuate the receptor activator of nuclear factor kappa-B ligand (RANKL)-induced activation of the MAPK and NF-κB pathways and also the activation of the Nrf2/HO-1 pathway. Vitexin reduces the production of inflammatory cytokines (TNF-α, IL-1β, and IL-6) and inhibits apoptosis in cells and tissues infected with Staphylococcus aureus. It also inhibits the recruitment of neutrophils and regulates the transcription factors of proinflammatory mediators, reducing the expression of p-p38, p-ERK1/2, and p-JNK in LPS-induced cells.

Studies have reported that vitexin represses the activation of the TLR4/NF-κB signaling pathway in colitis-associated liver injury. Vitexin also exerts anti-inflammatory effects on endothelial cell damage, acute lung injury, allergic asthma, and neuroinflammation. Studies indicate that vitexin possesses anti-inflammatory and analgesic properties in diverse inflammatory pain models by modulating macrophage polarization, inhibiting TRPV1 channel function, and regulating oxidative stress as well as cytokine production.

3.4 Anticancer Mechanisms

Preclinical studies demonstrate that vitexin modulates critical cellular processes such as cell cycle progression, apoptosis, autophagy, metastasis, angiogenesis, epigenetic modifications, and tumor glycolysis inhibition. It exerts its effects by targeting key signaling pathways, including PI3K/Akt/mTOR, NF-κB, and STAT3, and shows potential for combination therapies to enhance efficacy and overcome resistance.

Cancer-related cell mechanisms include growth inhibition via downregulation of the PI3K/Akt, mTOR, and MAPK signaling pathways; induction of apoptosis and autophagy through upregulation of p53, PUMA, Bax, PARP, p-JNK, cytochrome C, and Fas/FasL, and downregulation of caspases, Bcl-2, and ERK1/2; cell cycle arrest by downregulation of cyclin and cyclin-dependent kinases; inhibition of angiogenesis by downregulating HIF and VEGF pro-angiogenic factors; and suppression of cancer spread by decreasing MMPs and downregulating the oncogenic protein NF-κB.

3.5 Neuroprotective Mechanisms

Vitexin contributes to increasing neuroprotective factors and pathways and counteracts the targets that induce neurodegeneration, such as redox imbalance, neuroinflammation, abnormal protein aggregation, and reduction of cognitive and/or motor impairment. By reducing the levels of pro-inflammatory and cytotoxic factors in LPS-induced microglia and mediating the NF-κB signaling pathway, neuroprotective effects have been demonstrated. Research shows that vitexin can regulate cell activity through the AKT/mTOR, p53, or Bcl-2/Bax pathways.

3.6 Cardiovascular Mechanisms

Vitexin has a wide range of pharmacological effects, particularly protective effects on the cardiovascular system. Research has shown that vitexin plays an important role in the cardiovascular system by affecting the myocardium, blood vessels, and platelets through multiple signaling pathways. In endothelial cell models under high-glucose conditions, high glucose-induced phosphorylation of IκBα and IKK was blocked by vitexin, and high-glucose-induced NF-κB p65 nuclear translocation was prevented by vitexin; a NF-κB activity assay demonstrated that vitexin significantly suppressed the high-glucose-induced activity of NF-κB.

4. Scientific Evidence by Health Area

4.1 Neurodegenerative Diseases

4.1.1 Parkinson's Disease

In a preclinical study, the neuroprotective effect of vitexin isolated from Crataegus pinnatifida Bunge was examined in Parkinson's disease models both in vitro and in vivo. On SH-SY5Y cells, MPP⁺ treatment suppressed cell viability, induced apoptosis, and increased the Bax/Bcl-2 ratio and caspase-3 activity. Vitexin significantly improved these parameters. Further study disclosed that vitexin enhanced the phosphorylation of PI3K and Akt, which was downregulated by MPP⁺, an effect that could be blocked by PI3K inhibitor LY294002 and activated by PI3K activator IGF-1.

Vitexin at 10–40 μM protected dopaminergic neurons against MPP⁺-induced toxicity and apoptosis and decreased the expression of caspase-3 and the Bax/Bcl-2 ratio in a dose-dependent manner in SH-SY5Y cells. Vitexin at 50 mg/kg prevented bradykinesia and initial lesions caused by MPTP in a Parkinson's disease mouse model. In both in vitro and in vivo studies, vitexin was found to activate the PI3K/Akt signaling pathway.

Vitexin could be antagonistic to protein misfolding and aggregation. Studies have shown that it can also act as an inhibitor of monoamine oxidase B (MAO-B) enzyme, thereby increasing striatal dopamine levels and hence restoring the behavioural deficit in experimental PD models.

Evidence strength: Vitexin has been shown to act in these neuroprotective pathways in preclinical experiments with results that qualify it as a promising molecule for further investigations and development as an adjuvant drug for the treatment of neurodegenerative diseases. The results provide substantial evidence to support the scientific exploration of vitexin in these pathologies, since their effects are still little explored for this direction. All evidence is currently preclinical (in vitro and animal models); no human clinical trials specifically for vitexin in Parkinson's disease have been published.

4.1.2 Alzheimer's Disease

A study aimed to isolate the major compounds of Serjania erecta Radlk leaves and assess whether these compounds protect PC12 cells from Aβ25-35 peptide-induced toxicity. Three flavonoid glycosides were isolated with high purity: quercetrin, vitexin, and isovitexin. Treatment of PC12 cells with the flavonoids before exposure to the Aβ25-35 peptide increased cell viability, protecting the cells against toxicity. Vitexin promoted higher protection levels than quercetrin and isovitexin, and reduced lactate dehydrogenase release and NO production in Aβ25-35 peptide-treated cells.

In Alzheimer's disease, oxidative stress plays an important role in the onset and progression of pathology. The direct relationship between oxidative stress and the accumulation and abnormal aggregation of specific forms of Aβ peptides in senile plaques occurs through a positive feedback mechanism, where the generation of Aβ contributes to the generation of oxidative stress, which in turn activates the polymerization of beta-amyloid peptides.

Evidence strength: Preliminary; all evidence is from cell-based (in vitro) studies. No human clinical trials for vitexin in Alzheimer's disease have been reported.

4.1.3 Cerebral Ischemia and Stroke

In the treatment of cerebral ischemia–reperfusion injury (CIRI), vitexin can improve the behavior of CIRI mice and inhibit oxidative damage in the mouse brain, thereby showing its potential as a drug candidate for stroke treatment. Administration of vitexin at 50 mg/kg in vivo and 100 μM in vitro reduced sevoflurane anesthetic-induced neurotoxicity, and vitexin reduced the content of malondialdehyde (MDA) and increased levels of antioxidants SOD and GSH-Px. The protective effect of vitexin on reducing the volume of cerebral infarction and preserving cortical and hippocampal cells was evidenced in a preclinical model of middle cerebral artery occlusion (MCAO).

Evidence strength: Preclinical only (animal models and cell lines); no human clinical data available.

4.1.4 Seizure and Epilepsy Models

Vitexin, a flavone with antioxidant, anti-inflammatory, and neuroprotective properties, has been shown to suppress seizure activity in rodent models. Using zebrafish, one study further evaluated the antiseizure properties of vitexin and for the first time examined related flavone glycosides: isovitexin, vitexin-2-O-rhamnoside, vitexin-4-O-glucoside, and others. Research groups have shown that chronic exposure to vitexin also suppresses PTZ-induced kindling in animal models.

Evidence strength: Preclinical (rodent and zebrafish models); human clinical evidence is absent.

4.2 Antidepressant Activity

Vitexin at 10–30 mg/kg (i.p.) reduced the immobility time in both the tail-suspension test and the modified forced swimming test in mice, attributed to its antidepressant-like effects. The antidepressant effects of vitexin may be related to increasing catecholamine in the synaptic cleft, activating serotonergic 5-HT1A, noradrenergic α2, and dopaminergic D1, D2, and D3 receptors.

Evidence strength: Preclinical (mouse behavioral models); no human clinical trials have been conducted.

4.3 Cardiovascular System

Vitexin has a variety of pharmacological effects, including antioxidant, anti-inflammatory, anticancer, antinociceptive, and neuroprotective effects. A published review summarizes the protective effects of vitexin as an antioxidant against reactive oxygen species, lipid peroxidation, and other oxidative damages in a variety of oxidative stress-related diseases, including myocardial and respiratory injury.

In myocardial ischemia/reperfusion injury, vitexin has been studied in rodent models, where it was reported to attenuate injury by regulating mitochondrial dynamics imbalance. Vitexin's inhibition of high-glucose-induced NF-κB and p38 MAPK activation in human umbilical vein endothelial cells (HUVECs) provides mechanistic insight into potential protection against diabetic vascular complications. Studies published by different groups have shown that vitexin possesses many pharmacological effects, including antioxidative and anti-inflammatory properties, as well as cardiovascular protective effects.

Evidence strength: Predominantly preclinical (animal and cell-culture models). More basic research is needed on the antioxidative effects of vitexin in vivo, and carrying out clinical trials for the treatment of oxidative stress-related diseases is recommended.

4.4 Diabetes and Metabolic Function

Vitexin possesses a variety of biological properties including cardio-protective and hepato-pancreatic protective effects. Other reported health-relevant effects include fat reduction and glucose metabolism modulation.

In animal studies of diabetic complications, vitexin has been reported to suppress high-glucose-induced inflammatory and adhesion molecule expression in endothelial cells through NF-κB inhibition. In one study using alloxan-induced diabetic mice, mice receiving vitexin–isovitexin microspheres at both doses of 30 and 60 mg/kg showed a clear decrease in blood glucose levels and AUC after 21 days. The hypoglycemic effects of this preparation may be attributed to the pharmacological activities of vitexin and isovitexin combined with the bioavailability-enhancing actions of the microspheres. This result is consistent with various other studies that support the antidiabetic effects of vitexin and isovitexin.

The mung bean—one of the richest dietary sources of vitexin—has been documented to ameliorate hyperglycemia, hyperlipemia, and hypertension, and to prevent cancer and melanogenesis, as well as to possess hepatoprotective and immunomodulatory activities. However, these effects are attributable to the whole food matrix, and isolating the specific contribution of vitexin from other mung bean components in clinical contexts remains difficult.

Evidence strength: Preclinical (in vitro and animal models); no human randomized controlled trials specifically examining isolated vitexin in diabetes management have been reported in the literature surveyed.

4.5 Anticancer Activity

Preclinical studies demonstrate that vitexin modulates critical cellular processes such as cell cycle progression, apoptosis, autophagy, metastasis, angiogenesis, epigenetic modifications, and tumor glycolysis inhibition.

In nasopharyngeal carcinoma (NPC): Vitexin suppresses the activation of the NF-κB signaling pathway and its key regulators (p65, IκBα, and IKKs) in nasopharyngeal carcinoma cells, leading to apoptosis induction and inhibition of cell proliferation. In NPC xenograft mouse models, oral administration of vitexin at 30 mg/kg for two weeks reduces tumor growth by decreasing the expression levels of p-p65 and Cyclin D1.

In nasopharyngeal and other cancer cell lines: Vitexin at 10 and 20 μM for 24 hours suppressed the activation of NF-κB and its key regulators (p65, IκBα, and IKKs) and resulted in induction of apoptosis and inhibition of cell growth in nasopharyngeal carcinoma cells.

In renal cancer: In renal cancer cells (ACHN and OS-RC-2), vitexin significantly inhibits cell growth and induces apoptosis and hyperautophagy in a dose-dependent manner.

In a chronic myeloid leukemia cell line: Vitexin at 100 and 200 μg/mL (IC₅₀ = 147 μg/mL) as an active constituent of Prosopis cineraria had dose- and time-dependent anti-proliferative activity in a chronic myeloid leukemia (K-562) cell line by inducing apoptosis.

Evidence strength: All anticancer evidence for vitexin is currently preclinical, derived from in vitro cell line studies and xenograft mouse models. Plants have served as a cornerstone of medicinal compounds for millennia, yet the molecular characterization of their bioactive constituents—particularly their anticancer potential—has only recently gained scientific attention. No human clinical trials have tested vitexin as an anticancer agent.

4.6 Anti-inflammatory and Analgesic Activity

The inhibition of the NF-κB pathway provides substantial anti-inflammatory benefits in neuropathic pain models, while the ability to prevent neuronal apoptosis underlines vitexin's neuroprotective and therapeutic potential. Studies indicate that vitexin possesses anti-inflammatory and analgesic properties in diverse inflammatory pain models by modulating macrophage polarization, inhibiting TRPV1 channel function, and regulating oxidative stress as well as cytokine production.

Vitexin inactivated TRPV1 expression and thereby reduced pain in capsaicin-induced pain in in vivo studies.

Evidence strength: Preclinical (animal models of inflammatory pain); no human analgesic or anti-inflammatory clinical trials for isolated vitexin have been reported.

4.7 Hepatoprotective Activity

Vitexin has been identified in beetroot (Beta vulgaris var. cicla), and hepatoprotective flavone glycosides from the aerial parts of beetroot have been documented in the literature. Vitexin has a variety of pharmacological effects, including hepatoprotective effects. In preclinical models of liver injury, vitexin has been reported to attenuate injury through its antioxidative and anti-inflammatory actions, including repression of the TLR4/NF-κB signaling pathway in colitis-associated liver injury.

Evidence strength: Preclinical only; human clinical evidence is not available for vitexin specifically.

4.8 Antimicrobial Activity

Conducted studies showed that Vitex species exhibited in vitro antimicrobial activity against Bacillus subtilis, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Staphylococcus aureus. Vitex agnus-castus and Vitex negundo have been the most studied species, not only against bacterial strains but also against fungi such as Aspergillus niger and Candida albicans, viruses such as HIV-1, and parasites such as Plasmodium falciparum.

Evidence strength: In vitro antimicrobial data; clinical infectious disease evidence for isolated vitexin is absent.

5. Body Systems Associated with Vitexin

Vitexin has received increasing attention because of its wide range of pharmacological effects, including anticancer, antioxidant, anti-inflammatory, anti-Alzheimer's disease, blood pressure-lowering, and anti-hypoxia/ischemic injury activities. These pharmacological effects are related to multiple systems, such as the central nervous, cardiovascular, intestinal, and endocrine systems.

Central Nervous System: Neuroprotective, antidepressant, antiseizure, and cognitive-modulating activities demonstrated in preclinical models.
Cardiovascular System: Cardioprotective, antihypertensive, antiplatelet, and endothelial protective activities studied in animal models and cell lines.
Metabolic / Endocrine System: Antidiabetic, antilipidemic, and glucose-regulatory activities reported in animal studies.
Immune / Inflammatory System: Anti-inflammatory and analgesic effects across multiple preclinical models.
Oncology: Preclinical anticancer activities across multiple cancer cell types, with no human translation yet.
Hepatic System: Hepatoprotective effects demonstrated in preclinical models.
Reproductive / Hormonal System (plant-level): Vitex agnus-castus fruit extracts (containing vitexin) have a long traditional use in female reproductive health; however, other constituents of the plant (e.g., diterpenoids, agnuside) are considered more pharmacologically active for this use than vitexin specifically.
Gut Microbiota: Emerging research suggests that vitexin's ability to regulate gut bacteria contributes to its neuroprotective effects, potentially offering a novel approach for treating neurodegenerative diseases.

6. Pharmacokinetics, Bioavailability, and Dosage Forms

6.1 Bioavailability Challenges

Clinical application of vitexin faces several significant challenges, primarily due to its poor aqueous solubility, limited intestinal permeability, and extensive first-pass metabolism, which collectively reduce bioavailability. Studies obtained 94%, 30%, and 5% as the intestinal, gastric, and hepatic first-pass effects, respectively, leading to the low bioavailability of vitexin.

For the related compound vitexin rhamnoside: vitexin rhamnoside was eliminated with a systemic clearance of 1.07 ± 0.26 L/h/kg, a half-life of 0.72 ± 0.15 h, a volume of distribution of 1.09 ± 0.22 L/kg, and a time to maximum plasma concentration of 0.92 ± 0.14 h following intravenous administration, contributing to its low bioavailability.

Studies have suggested that the use of liposomes, nanoparticles, and micelles as drug delivery systems could enhance vitexin bioavailability in vitro. Another proposed way of increasing the bioavailability of flavonoids is via food supplements.

6.2 Novel Delivery Systems Being Investigated

The oral bioavailability of vitexin in one nanoparticle system increased by 5.6-fold compared to free vitexin. A mPEG-g-CTS/ALG polyelectrolyte complex nanoparticle delivery system enhances vitexin's gastrointestinal digestion and is suitable for oral, intestinal-specific delivery, offering a new approach for improving absorption and bioavailability. Liposomal encapsulation using the thin-film hydration method provides an effective strategy for treating liver cirrhosis by enhancing the bioavailability and therapeutic effectiveness of vitexin through oral delivery. Vitexin-rhamnoside and zein-VR-pectin nanoparticles have been found to improve the bioavailability of vitexin while alleviating chronic inflammation and hepatic injury in high-fat diet (HFD) mice.

6.3 Dosages Reported in Preclinical Studies

The following dosages are those reported in the cited preclinical literature and should not be interpreted as clinical dosing guidance:

10–40 μM vitexin protected dopaminergic neurons against MPP⁺-induced toxicity in cell culture; 50 mg/kg vitexin (in vivo, mice) prevented bradykinesia in a Parkinson's disease model.
10–30 mg/kg (i.p.) reduced immobility time in antidepressant behavioral tests in mice.
30 mg/kg oral vitexin for two weeks reduced tumor growth in NPC xenograft mouse models.
10 and 20 μM vitexin for 24 hours suppressed NF-κB in nasopharyngeal carcinoma cells in vitro.
30 and 60 mg/kg doses of vitexin–isovitexin microspheres showed dose-dependent blood-glucose-lowering effects in alloxan-induced diabetic mice after 21 days.
Long-term repeated use of high-dose vitexin at 10 mg/kg (i.p.) was shown to be safe in liver and gastric mucosal injury models.

7. Safety, Toxicology, and Drug Interactions

7.1 General Safety Profile

Vitexin did not cause significant toxic reactions, even at high doses in in vivo experiments. Generally, flavonoids have not been linked with any adverse health effects and are generally considered to be beneficial. The apigenin flavone class is generally known for low toxicity.

Though flavones show promising results in preclinical studies, their bioavailability, toxicological profile, and clinical efficacy in human subjects still need to be explored thoroughly before use.

7.2 Dose-Dependent Toxicity Signals

While animal studies indicate low systemic toxicity, zebrafish embryo models reveal dose-dependent risks: concentrations ≥ 100 μM reduce survival rates, impair cardiac function, and increase ROS-mediated apoptosis. Clinical translation must address its dual redox effects—exerting antioxidant protection at low doses but potentially triggering pro-oxidant toxicity at high doses or under specific microenvironments.

In an acute toxicity study using OECD guidelines: three doses of vitexin–isovitexin (2 g/kg, 5 g/kg, 10 g/kg) were evaluated for signs of acute toxicity in mice during a 14-day observation period. Microencapsulation was noted to be a promising strategy for improving stability, bioavailability, and biocompatibility.

7.3 Drug–Drug Interaction Potential

Pharmacokinetic interactions are critical, as in vitro studies confirm that vitexin's inhibition of CYP3A4 and P-glycoprotein (P-gp) may alter the metabolism of drugs like paclitaxel, necessitating optimized dosing strategies in combination regimens. This interaction has been identified only in vitro; the clinical relevance of this finding has not been established in human pharmacokinetic studies. CYP3A4 is involved in the metabolism of a broad range of pharmaceutical agents, meaning that theoretical interactions with a wide range of co-administered drugs are plausible, though unconfirmed in humans.

7.4 Absence of Human Clinical Trials

The pharmacological mechanisms, clinical efficacy, and potential synergistic effects of vitexin with other therapeutic agents remain unclear. Further systematic research is needed to clarify molecular targets and optimize therapeutic applications. Clinical studies are needed to further examine the protective effects of vitexin against oxidative stress-related diseases; nanoparticles of vitexin have been developed for increasing bioavailability to help address this need. As of the literature reviewed, there are no published randomized controlled trials in humans testing isolated vitexin as a primary intervention for any indication.

8. Summary of Evidence Strength

Chemical and structural characterization: Well-established. Extensive peer-reviewed literature confirms the compound's identity, structure, and source plants.
In vitro mechanisms (antioxidant, anti-inflammatory, anticancer, neuroprotective): Strong body of in vitro cell-line data; mechanistic pathways well-characterized.
In vivo preclinical evidence (animal models): Substantial evidence in rodent models for neuroprotection, cardioprotection, antidiabetic, antitumor, and antidepressant effects.
Human clinical evidence: Absent for isolated vitexin. This highlights a need for a comprehensive evaluation of the pharmacological properties, pharmacokinetics, and clinical relevance of vitexin, highlighting its potential in disease prevention and treatment.
Bioavailability: Currently poor with standard oral administration; nanoparticle and liposomal strategies under active development.
Safety: Generally low acute toxicity in animal studies; dual redox behavior at high doses warrants attention; potential for CYP3A4 and P-gp interactions based on in vitro data.

References

Health Conditions

Health conditions that Vitexin may help support.

No conditions available.

Body Systems

Body systems that Vitexin may help support.

No body systems available.